Adalimumab in crohn's disease: Tips and tricks after 5 years of clinical experience

Current Medicinal Chemistry

Volumn 18, Issue 8, 2011, Pages 1230-1238

  Fiorino, G ^a,b   Szabo H ^a   Fries, W ^b   Malesci, A ^a,c   Peyrin Biroulet, L ^d   Danese, S ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

Adalimumab; Crohn's disease; Efficacy; Inflammatory bowel disease; Safety

Indexed keywords

ADALIMUMAB; CD40 ANTIGEN; CD40 LIGAND; CERTOLIZUMAB PEGOL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 12; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL INFECTION; APOPTOSIS; ARTICLE; BASAL CELL CARCINOMA; COST BENEFIT ANALYSIS; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLATULENCE; FOLLOW UP; GASTROINTESTINAL INFECTION; HEADACHE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; INHIBITION KINETICS; INJECTION SITE REACTION; INTESTINE SURGERY; LUNG INFECTION; LYMPHOMA; NAUSEA; NONHODGKIN LYMPHOMA; PELVIC INFLAMMATORY DISEASE; PERIANAL ABSCESS; PHARYNGITIS; PNEUMONIA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHINOPHARYNGITIS; SKIN CANCER; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS INFECTION; SYSTEMATIC REVIEW; T LYMPHOCYTE; THRUSH; TREATMENT OUTCOME; TUBERCULOSIS;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; HUMANS; REMISSION INDUCTION;

EID: 79952802478     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795029726     Document Type: Article

References (65)

1. Peyrin-Biroulet, L.; Loftus E.V.; Colombel, J.F.; Sandborn, W.J. The natural history of adult Crohn's disease in population-based cohorts. Am. J. Gastroenterol., 2010, 105(2), 289-297.
2. Vernier-Massouille, G.; Balde, M.; Salleron, J.; Turck, D.; Dupas, J.L.; Mouterde, O.; Merle, V.; Salomez, J.L.; Branche, J.; Marti, R.; Lerebours, E.; Cortot, A.; Gower-Rousseau, C.; Colombel, J.F. Natural history of pediatric Crohn's disease: A population based cohort study. Gastroenterology, 2008, 135(4), 1106-1113.
3. Pennica, D.; Cosnes, J.; Cattan, S. ; Blain, A .; Beaugerie, L. ; Carbonnel, F. ; Parc, R. ; Gendre, J.P, Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature, 1984, 312, 724-729. (Pubitemid 15195918)
4. Tansey, MG.; Szmkowski, D.E. The TNF superfamily in 2009: New pathways, new indications, and new drugs. Drug Discov. Today, 2009, 14, 1082-1088.
5. Seko, Y.; Cole, S.; Kasprzak, W.; Shapiro, B.A.; Ragheb, J.A. The role of cytokine mRNA stability in the pathogenesis of autoimmune disease. Autoimmun Rev., 2006, 5(299-305). (Pubitemid 43868196)
6. Murch, S.H.; Lamkin, V.A.; Savage MO, Walker-Smith, J.A.; MacDonald, T.T. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut, 1991, 32, 913-917.
7. Braegger, C.P.; Nicholls, S.; Murch, S.H.; Stephens, S.; MacDonald, T.T. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet, 1992, 339, 89-91.
8. Breese, E.J.; Michie, C.A.; Nicholls, S.W.; Murch, S.H.; Williams, C.B.; Domizio, P.; Walker-Smith J.A.; MacDonald, T.T. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology, 1994, 106(1455-1466). (Pubitemid 24163114)
9. Van Dullemen, H.M.; van Deventer, S.J.; Hommes, D.W.; Bijl, H.A.; Jansen, J.; Tytgat, G.N.; Woody, J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology, 1995, 109(1), 129-135.
10. Cosnes, J.; Cattan, S.; Blain, A.; Beaugerie, L.; Carbonnel, F.; Parc, R.; Gendre, J.P. Long-term evolution of disease behavior of Crohn's disease. Inflamm. Bowel Dis., 2002, 8(4), 244-250. (Pubitemid 34784976)
11. Nesbitt, A.; Fossati, G.; Bergin, M.; Stephens, P.; Stephens, S.; Foulkes, R.; Brown, D.; Robinson, M.; Bourne, T. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm. Bowel Dis., 2007, 13(11), 1323-1332. (Pubitemid 350206841)
12. Danese, S.; Pagano, N.; Angelucci, E.; Stefanelli, T.; Repici, A.; Omodei, P.; Daperno, M.; Malesci, A. Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: Tipping the balance. Curr. Med. Chem., 2007, 14, 1489-1497. (Pubitemid 46902211)
13. Karmiris, K; Paintaud,G.; Noman, M.; Magdelaine-Beuzelin, C.; Ferrante, M.; Degenne, D.; Claes, K.; Coopman, T.; Van Schuerbeek, N.; Van Assche, G.; Vermeire, S.; Rutgeerts, P. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology, 2009, 137(5), 1628-1640.
14. Tracey, D.; Cosnes, J.; Cattan, S.; Blain, A.; Beaugerie, L; Carbonnel, F.; Parc, R.; Gendre, J.P. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther., 2008, 117, 244-279.
15. Nesbitt A.M.; Fossati, G.; Brown, D.T. Comparison of certolizumab pegol, etanercept, adalimumab and infliximab: Effect on lipopolysaccharide-induced cytokine production by human peripheral blood monocytes. Am. J. Gastroenterol., 2006, S420-470.
16. Ljung, T.; Axelsson, L.G.; Herulf, M.; Lundberg, J.O.; Hellström, P.M. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment. Aliment. Pharmacol. Ther., 2007, 25(8), 925-932. (Pubitemid 46525348)
17. Agnholt, J.; Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine, 2001, 15(4), 212-222. (Pubitemid 34587646)
18. Agnholt, J.; Kelsen, J.; Brandsborg, B.; Jakobsen, N.O.; Dahlerup, J.F. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease-a possible target for infliximab treatment. Eur. J. Gastroenterol. Hepatol., 2004, 16(7), 649-655. (Pubitemid 38901632)
19. Di Sabatino, A.; Ciccocioppo, R.; Cinque, B.; Millimaggi, D.; Morera, R.; Ricevuti, L.; Cifone, M.G.; Corazza, G.R. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut, 2004, 53, 70-77. (Pubitemid 38083013)
20. ten Hove, T.; van Montfrans, C.; Peppelenbosch, M.P.; van Deventer, S.J. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut, 2002, 50, 206-211. (Pubitemid 34087933)
21. Shen, C.; Assche, G.; Colpaert, S.; Maerten, P.; Geboes, K.; Rutgeerts, P.; Ceuppens, J.L. Adalimumab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept. Aliment. Pharmacol. Therap., 2005, 21, 251-258. (Pubitemid 40278362)
22. Fossati, G.; Nesbitt, A. Effect of the anti-TNF agents, adalimumab, Etanercept, Infliximab, and Certolizumab PEGOL (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. Am. J. Gastroenterol., 2005, 100, S298-299.
23. Fries, W.; Muja, C.; Crisafulli, C.; Costantino, G.; Longo, G.; Cuzzocrea, S.; Mazzon, E. Infliximab and etanercept are equally effective in reducing enterocyte APOPTOSIS in experimental colitis. Int. J. Med. Sci., 2008, 5(4), 169-180. (Pubitemid 352000027)
24. Zeissig, S.; Bojarski, C.; Buergel, N.; Mankertz, J.; Zeitz, M.; Fromm, M., Schulzke, J.D. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut, 2004, 53(9), 1295-1302. (Pubitemid 39120115)
25. Eastaff-Leung, N.; Mabarrack, N.; Barbour, A.; Cummins, A.; Barry, S. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J. Clin. Immunol., 2010, 30(1), 80-89.
26. Li, Z.; Arijs I.; De Hertogh, G.; Vermeire, S.; Noman, M.; Bullens, D.; Coorevits, L.; Sagaert, X.; Schuit, F.; Rutgeerts, P.; Ceuppens, J.L.; Van Assche, G. Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab. Inflamm. Bowel Dis., 2010, 16(8), 1299-1310.
27. Ley, K. The role of selectins in inflammation and disease. Trends Mol. Med., 2003, 9, 263-268. (Pubitemid 36841686)
28. Mitoma, H.H., T.; Tsukamoto, H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. Gastroenterology, 2004, 26, 934-935.
29. Borcherding, F.; Nitschke, M.; Hundorfean, G.; Rupp, J.; von Smolinski, D.; Bieber, K.; van Kooten, C.; Lehnert, H.; Fellermann, K.; Büning, J. The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease. Am. J. Gastroenterol., 2010, 176, 1816-1827.
30. Medina, C.; Radomski M.W. Role of matrix metalloproteinases in intestinal inflammation. J. Pharmacol. Exp. Ther., 2006, 318, 933-938. (Pubitemid 44268297)
31. Di Sabatino, A.; Pender, S.L.; Jackson, C.L.; Prothero, J.D.; Gordon, J.N.; Picariello, L.; Rovedatti, L.; Docena, G.; Monteleone, G.; Rampton, D.S.; Tonelli, F.; Corazza, G.R.; MacDonald, T.T. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology, 2007, 133(1), 137-149. (Pubitemid 47031137)
32. Hanauer, S.B.; Sandborn, W.; Rutgeerts, P.; Fedorak, R.N.; Lukas, M.; Macintosh, D.; Panaccione, R.; Wolf, D.; Pollack, P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in crohn's disease: The CLASSIC-I Trial. Gastroenterology, 2006, 130(2), 323-333.
33. Sandborn, W.J.; Rutgeerts, P.; Enns, R.; Hanauer, S.B.; Colombel, J.F.; Panaccione, R.; D'Haens, G.; Li, J.; Rosenfeld, M.R.; Kent, J.D.; Pollack, P.F. Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial. Ann. Intern. Med., 2007, 146(12), 829-838. (Pubitemid 351650483)
34. Seiderer, J.; Brand, S.; Dambacher, J.; Pfennig, S.; Jürgens, M.; Göke, B.; Ochsenkühn, T. Adalimumab in patients with Crohn's disease-safety and efficacy in an open-label single centre study. Aliment. Pharmacol. Ther., 2007, 25, 787-796. (Pubitemid 46434910)
35. Youdim, A.; Vasiliauskas, E.A.; Targan, S.R.; Papadakis, K.A.; Ippoliti, A.; Dubinsky, M.C.; Lechago, J.; Paavola, J.; Loane, J.; Lee, S.K,; Gaiennie, J.; Smith, K.; Do, J.; Abreu, M.T. , A pilot study of adalimumab in infliximaballergic patients. Inflamm. Bowel Dis., 2004, 10, 333-338. (Pubitemid 39029174)
36. Hinojosa, J.; Gomollòn, F.; García, S.; Bastida, G.; Cabriada, J.L.; Saro, C.; Ceballos, D.; Peñate, M.; Gassull, M.A. Spanish Scientific Group on Crohn's Disease and Ulcerative Colitis, Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: A prospective, open-label, multicentre trial. Aliment. Pharmacol. Ther., 2007, 25, 409-418. (Pubitemid 46184454)
37. Peyrin-Biroulet, L.; Laclotte, C.; Bigard, M.A. Adalimumab maintenance therapy for Crohn's disease with intolerance or lost response to infliximab: An open-label study. Aliment. Pharmacol. Ther., 2007, 25, 675-680.
38. Ho, G.T.; Mowat, A.; Potts, L.; Cahill, A.; Mowat, C.; Lees, C.W.; Hare, N.C.; Wilson, J.A.; Boulton-Jones, R.; Priest, M.; Watts, D.A.; Shand, A.G.; Arnott, I.D.; Russell, R.K.; Wilson, D.C.; Morris, A.J.; Satsangi, J. Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: Analysis of nationwide experience in Scotland (2004-2008). Aliment. Pharmacol. Ther., 2009, 29, 527-534.
39. Sandborn, W.J.; Hanauer, S.; Loftus, E.V.; Tremaine, W.J.; Kane, S.; Cohen, R.; Hanson, K.; Johnson, T.; Schmitt, D.; Jeche, R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am. J. Gastroenterol., 2004, 99, 1984-1989. (Pubitemid 39421244)
40. Oussalah, A.; Babouri, A.; Chevaux, J.B.; Stancu, L.; Trouilloud, I.; Bensenane, M.; Boucekkine, T.; Bigard, M.A.; Peyrin-Biroulet, L. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: A 3-year single-centre experience. Aliment Pharmacol. Ther., 2009, 29(4), 416-423.
41. Sandborn, W.J.; Hanauer S.; Rutgeerts, P.; Fedorak, R.N.; Lukas, M.; MacIntosh, D.G.; Panaccione, R.; Wolf, D.; Kent, J.D.; Bittle, B.; Li, J.; Pollack, P.F. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut, 2007, 56(9), 1232-1239. (Pubitemid 47300424)
42. Colombel, J.F.; Sandborn,W.; Rutgeerts, P.; Enns, R.; Hanauer, S.B.; Panaccione, R.; Schreiber, S.; Byczkowski, D.; Li, J.; Kent, J.D.; Pollack, P.F. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology, 2007, 132(1), 52-65. (Pubitemid 46108762)
43. Panaccione, R.; Colombel, J.F.; Sandborn, W.J.; Rutgeerts, P.; D'Haens, G.R.; Robinson, A.M.; Chao, J.; Mulani, P.M.; Pollack, P.F. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment. Pharmacol. Ther., 2010, 31(12), 1296-1309.
44. Lichtiger, S.; Binion, D.; Wolf, D.C.; Present, D.H.; Lomax, K.G.; Kent, J.D.; Cardoso, A.T.; Lau, W. Adalimumab safety in patients with Crohn's disease and previous exposure to infliximab: CHOICE trial. Gastroenterology, 2008, 134, A489.
45. Lofberg, R.; Louis, E.; Reinisch, W. Adalimumab effectiveness in TNFantagonist- naïve patients and in infliximab nonresponders with Crohn's disease: Results from the CARE study. Am. J. Gastroenterol., 2008, 103, S414-415.
46. Ma, C.; Panaccione, R.; Heitman, S.J.; Devlin, S.M.; Ghosh, S.; Kaplan, G.G. Systematic review: The short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment. Pharmacol. Ther., 2009, 30(10), 977-986.
47. Van Assche, G.; Vermeire, S.; Ballet, V.; Noman, M.; D'Haens, G.; Humblet, E.H.; Claessens, C.; Rutgeerts, P. 645 Switch to Adalimumab in Patients With Crohn's Disease Controlled by Maintenance Infliximab. the Prospective Randomized Switch Study. Gastroenterology, 2010, 138(5, Supplement 1), S-85.
48. Colombel, J.F.; Schwartz, D.; Sandborn, W.J.; Kamm, M.A.; D'Haens, G.; Rutgeerts, P.; Enns, R.; Panaccione, R.; Schreiber, S.; Li, J.; Kent, J.D.; Lomax, K.G.; Pollack, P.F. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut, 2009, 58(7), 940-948.
49. Ng, S.C.; Plamondon, S.; Gupta, A.; Burling, D.; Kamm, M.A. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas. Aliment. Pharmacol. Ther., 2009, 30(7), 757-766.
50. Van Assche, G.; Dignass, A.; Reinisch, W.; van der Woude, C.J.; Sturm, A.; De Vos, M.; Guslandi, M.; Oldenburg, B.; Dotan, I.; Marteau, P.; Ardizzone, A.; Baumgart, D.C.; D'Haens, G.; Gionchetti, P.; Portela, F.; Vucelic, B.; Söderholm, J.; Escher, J.; Koletzko, S.; Kolho, K. L.; Lukas, M.; Mottet, C.; Tilg, H.; Vermeire, S.; Carbonnel, F.; Cole, A.; Novacek, G.; Reinshagen, M.; Tsianos, E.; Herrlinger, K.; Oldenburg, B.; Bouhnik, Y.; Kiesslich, R.; Stange, E.; Travis, S.; Lindsay, J. For the European Crohn's and Colitis Organisation (ECCO), The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J. Crohn's Colitis, 2010, 4, 63-101.
51. Colombel, J.F.; Rutgeerts, P.; Sandborn, W.J,; Camez, A.; Pollack, P.F.; Chen, N.; Yang, M.; Chao, J.; Mulani, P.M. Deep remission for adalimumab treated patients with moderate to severe ileocolonic crohn's disease: Results from extend. J. Crohn Colitis, 2010, 4(1), S3.
52. Loftus, E.V.; Feagan, B., Colombel, J.F.; Rubin, D.T.; Wu, E.Q.; Yu, A.P.; Pollack, P.F.; Chao, J.; Mulani, P. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. Am. J .Gastroenterol., 2008, 103(12), 3132-3141.
53. Bodger, K.; Kikuchi, T.; Hughes, D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment. Pharmacol. Ther., 2009, 30, 265-274.
54. Feagan, B.G.; Panaccione, R.; Sandborn, W.J.; D'Haens, G.R.; Schreiber, S.; Rutgeerts, P.J.; Loftus, E.V.; Lomax, K.G.; Yu, A.P.; Wu, E.Q.; Chao, J.; Mulani, P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: Results from the CHARM study. Gastroenterology, 2008, 135(5), 1493-1499.
55. Fiorino, G.; Danese, S.; Peyrin-Biroulet, L. In Clinical Update on Inflammatory Disorders of the Gastrointestinal Tract. Tilg H, M.J., Ed.; Karger AG: Basel, 2010; Vol. 26, pp. 95-107.
56. Oussalah, A.; Danese, S.; Peyrin-Biroulet, L. Efficacy of TNF antagonists beyond one year in adult and pediatric inflammatory bowel diseases: A systematic review. Curr. Drug Targets, 2010, 11, 156-175.
57. Colombel, J.F.; Sandborn, W.; Panaccione, R.; Robinson, A.M.; Lau, W.; Li, J.; Cardoso, A.T. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis., 2009, 15(9), 1308-1319.
58. Peyrin-Biroulet, L.; Deltenre P.; de Suray, N.; Branche, J.; Sandborn, W.J.; Colombel, J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol., 2008, 6(6), 644-653. (Pubitemid 351783447)
59. Gisbert, J.P. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding. Inflamm. Bowel Dis., 2010, 16(881-895).
60. Pentsuk, N.; van der Laan, J.W. An interspecies comparison of placental antibody transfer: New insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res., 2009, 86, 328-344.
61. Simister, N.E. Placental transport of immunoglobulin G. Vaccine, 2003, 21, 3365-3369. (Pubitemid 36792087)
62. Jürgens, M.; Brand, S.; Filik, L.; Hübener, C.; Hasbargen, U.; Beigel, F.; Tillack, C.; Göke, B.; Ochsenkühn, T.; Seiderer, J. Safety of adalimumab in Crohn's disease during pregnancy: Case report and review of the literature. 2010, 2010, 16(10), 1634-1636.
63. http://clinicaltrials.gov/ct2/show/NCT00524537?term=Adalimumab+long+ term+safety+Crohn&rank=3. Accessed on 29 December 2010.
64. Colombel, J.F.; Sandborn, W.; Reinisch, W.; Mantzaris, G.J.; Kornbluth, A.; Rachmilewitz, D.; Lichtiger, S.; D'Haens, G.; Diamond, R.H.; Broussard, D.L.; Tang, K.L.; van der Woude, C.J.; Rutgeerts, P. SONIC Study Group, Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med., 2010, 362(15), 1383-1395.
65. Regueiro, M.; Schraut,W.; Baidoo, L.; Kip, K.E.; Sepulveda, A.R.; Pesci, M.; Harrison, J.; Plevy, S.E. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology, 2009, 136(2), 441-450.